<DOC>
	<DOCNO>NCT00804544</DOCNO>
	<brief_summary>99mTc-SestaMIBI mammoscintigraphy ( MMS ) may use patient locally advance breast cancer ( LABC ) schedule neoadjuvant chemotherapy . MMS may perform 1 ) nodal stag axillary lymph node metastasis , 2 ) prediction chemosensitivity Pgp/MDR-1 mediate chemoresistance , 3 ) evaluation efficacy chemotherapy radiation therapy . MMS routinely perform planar/SPECT image accord Society Nuclear Medicine European Association Nuclear Medicine guideline . In pilot study , optimised acquisition protocol setup SPECT/low-dose multislice CT addition planar imaging .</brief_summary>
	<brief_title>99mTc-MIBI SPECT/CT Breast Malignancy</brief_title>
	<detailed_description>99mTc-SestaMIBI lipophylic cation many cytotoxic chemotherapy drug ( i.e . anthracyclines , inhibitor topoisomerase II , antimicrotubule , vinca alkaloid , inhibitor DNA replication ) accumulate mitochondrion tumour cell . MIBI tumour uptake relate viability proliferation due increase perfusion increase energy-dependent metabolism . 99mTc-SestaMIBI substrate glycoprotein P ( Pgp ) pump encode multidrug resistance gene -1 ( MDR-1 ) . MIBI tumour uptake significant wash-out time ( &lt; 45 % 3H ) predict chemosensitivity Pgp/MDR-1 overexpression . MIBI efflux significant tumour uptake predicts efflux chemotherapy drug tumour cell related Pgp/MDR-1 overexpression anti-apoptotic Bcl-2 overexpression . Early MIBI efflux ( &lt; 1H ) may also relate pro-apoptotic Bax overexpression . SPECT/CT use anatomic localisation attenuation correction . CT SPECT/CT low-dose ( &lt; 2 mSv ) multislice CT ( 4 slice ) . SPECT/CT also use correction image-degrading factor include collimator-detector-response compensation resolution recovery , scatter correction . SPECT/CT base absolute semi-quantification MIBI uptake primary tumour lymph node ( i.e . standardise uptake value SUV ) also perform . SPECT/CT optimise image compare planar/SPECT conventional nuclear image 1 ) detection MIBI-avid primary breast tumour lymph node metastasis , 2 ) semi-quantification MIBI uptake ( T/B , SUV , % wash-out ) primary breast tumour lymph node metastasis , 3 ) prediction chemosensitivity baseline , 3 ) Evaluation chemotherapy efficacy first course chemotherapy ( 2 week ) compare clinical response histo-pathological response . SPECT/CT mammoscintigraphy finding compare clinical finding ( palpation ) , radiological finding ( mammography , US , MRI ) , histo-pathological finding ( Pgp/MDR-1 expression ) tumours surgery .</detailed_description>
	<criteria>Patients histologically proven breast cancer Patients locally advance breast cancer ( stage T24 N03 M0 ) Patients schedule neoadjuvant chemotherapy Patients schedule radical modify mastectomy Patients physical and/or psychological contraindication Patients recent nuclear medicine study use longlived isotope ( i.e . 67Ga , 111In , 131I ) within 48 hour precede mammoscintigraphy Patient histologically proven breast cancer Patients early stage T1 breast cancer Patients candidate neoadjuvant chemotherapy Patients surgical candidate Patients physical and/or psychological contraindication Pregnant breast feeding patient Patients recent nuclear medicine study use longlived isotope ( i.e . 67Ga , 111In , 131I ) within 48 hour precede mammoscintigraphy</criteria>
	<gender>Female</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Integrated SPECT/CT</keyword>
	<keyword>99mTc-sestMIBI</keyword>
	<keyword>Chemosensitivity</keyword>
</DOC>